The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Gastrointestinal Tumors
Interventions
DRUG

propranolol (beta-blocker used treat high blood pressure)

Enrolled patients began receiving propranolol alone orally twice daily (10 mg bid) 10-14 days prior to surgery, and after 3 days of treatment, the dose of propranolol was increased to 20 mg bid daily until the day of surgery if the following three predefined criteria were met: systolic blood pressure greater than 90 mmHg, heart rate greater than 60 bpm, and no significant symptoms (e.g., syncope, insomnia, fatigue). The patient continues to be treated from 1 week after surgery.From 1 week after surgery, patients continue propranolol for 3 weeks. Patients will be monitored daily for symptoms, blood pressure, and heart rate and will be followed for observation at 6, 12, and 24 months after surgery until disease progression or clinical death, unless intolerable toxicity occurs and the patient refuses to continue treatment. The efficacy and safety of the preoperative propranolol β-blockade regimen in patients with gastrointestinal tract tumors was evaluated using the study objectives in S

Trial Locations (1)

200040

RECRUITING

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER